Catalio Capital Management, a multi-strategy life sciences investment firm with more than $1 billion in assets under management, has launched a dedicated public equities hedge fund investment strategy focused on identifying compelling life science investment opportunities globally.

Catalio Capital Management (Catalio), a multi-strategy life sciences investment firm with more than $1 billion in assets under management, has launched a dedicated public equities hedge fund investment strategy focused on identifying compelling life science investment opportunities globally. 

In connection with the launch of the vehicle, the investment team from HealthCor Management (HealthCor), a healthcare hedge fund with a two-decade track record, along with key members of its operations, financial, administrative and marketing divisions, have agreed to join Catalio to help build out the strategy.
  
HealthCor’s founders, Art Cohen and Joe Healey, both long-time supporters and early investors in Catalio, will join the firm as senior advisors.
  
The launch of its public equities strategy follows the close of Catalio’s ~$400 million Catalio Nexus Fund III, which has already made investments in more than twenty leading biotech companies, as well as the launch of the Structured Opportunities Fund, ahead of demand for structured credit and venture debt.